EPISODE · Jul 11, 2015 · 19 MIN
Podcast 179: Pradaxa (dabigatran) reversal near?
from Clinical Conversations · host NEJM Group
Running time: 20 minutes The anticoagulant dabigatran, marketed in the U.S. as Pradaxa, has always had the problem that, although it’s more convenient to use, there’s no sure way to stop its effect if the patient has a major bleed. Now, a monoclonal antibody fragment called idarucizumab (pronounced i-DARE-you-scis-ooh-mab) shows promise as a reversal agent. In an interim analysis of the first 90 of a planned 300 patients, the fragment was quite effective in stopping bleeds. The analysis was published in the New England Journal of Medicine, and we talk with the paper’s first author, Charles V. Pollack, Jr. Link to NEJM article (free) The post Podcast 179: Pradaxa (dabigatran) reversal near? first appeared on Clinical Conversations.
Embed this episode
What this episode covers
Running time: 20 minutes The anticoagulant dabigatran, marketed in the U.S. as Pradaxa, has always had the problem that, although it’s more convenient to use, there’s no sure way to stop its effect if the patient has a major bleed. Now, a monoclonal antibody fragment called idarucizumab (pronounced i-DARE-you-scis-ooh-mab) shows promise as a reversal agent. In an […]
NOW PLAYING
Podcast 179: Pradaxa (dabigatran) reversal near?
No transcript for this episode yet
Similar Episodes
No similar episodes found.
Similar Podcasts
No similar podcasts found.